{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:42:12Z","timestamp":1788964932309,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study aimed to develop active surveillance programs (ASPs) for anaphylaxis using the China Hospital Pharmacovigilance System (CHPS) and analyze the characteristics, allergens, and management strategies for anaphylaxis within a tertiary hospital setting in China.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We retrospectively analyzed the anaphylaxis cases reported to the National Adverse Drug Reaction Monitoring System in our hospital from 2014 to 2021. Characteristic medical orders, progress notes, and diagnoses in these cases were recorded to identify initial anaphylaxis trigger entries. Based on these initial entries, the questionnaire was developed, and the Delphi method was used to establish consensus entries for anaphylaxis triggers. The CHPS was used to program these trigger entries and construct ASPs, which were then tested on the 238,194 discharged patients to evaluate their performance and analyze the related clinical data.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Ten anaphylaxis triggers and three ASPs were ultimately identified. The ASPs captured 309 cases, out of which 94 cases were confirmed as anaphylaxis following manual screening. After removing duplicates, we noted 76 patients who experienced anaphylaxis 79 times. The positive rate of triggers and the positive predictive value of the programs were 0.13% and 30.42%, respectively. The incidence of anaphylaxis in our study was 0.03%, and the number of anaphylaxis cases detected by the ASPs was 5.64 times higher than those detected by the spontaneous reporting system. Anaphylaxis was more common among female patients. Antibacterial drugs, antineoplastic drugs, and contrast media were the most prevalent allergens in clinical practice. Anaphylaxis to antineoplastic drugs had the highest incidence (0.6%) when compared with patients admitted during the same period. Our study revealed a significant underuse of epinephrine and overuse of second-line therapy (glucocorticoids and antihistamines) in the management of anaphylaxis. Furthermore, we found the use and dosage of epinephrine to be inappropriate.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The CHPS can effectively utilize both structured and unstructured data to construct anaphylaxis ASPs, and this could counteract the under-reporting by the spontaneous reporting system, the primary adverse reaction monitoring method in China. The treatment and management of anaphylaxis are currently inadequate and require improvement to reduce mortality risk.<\/jats:p>","DOI":"10.3389\/fphar.2023.1180685","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T04:34:55Z","timestamp":1689050095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System"],"prefix":"10.3389","volume":"14","author":[{"given":"Chengcheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zejing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"B1","unstructured":"Announcement of the state food and drug administration on the revision of the insert of oxaliplatin2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1179\/1973947814y.0000000204","article-title":"Oxaliplatin-induced hypersensitivity reaction: Underlying mechanisms and management","volume":"27","author":"Aroldi","year":"2015","journal-title":"J. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaip.2013.08.012","article-title":"Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: Patient characteristics, management, and 1-year follow-up","volume":"2","author":"Banerji","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/ede.0000000000001330","article-title":"Identification and validation of anaphylaxis using electronic health data in a population-based setting","volume":"32","author":"Bann","year":"2021","journal-title":"Epidemiology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jaci.2021.07.035","article-title":"Anaphylaxis knowledge gaps and future research priorities: A consensus report","volume":"149","author":"Dribin","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.iac.2021.10.002","article-title":"Anaphylaxis: Data gaps and research needs","volume":"42","author":"Dribin","year":"2022","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/aci.0000000000000411","article-title":"Drug-induced anaphylaxis: Is it an epidemic?","volume":"18","author":"Giavina-Bianchi","year":"2018","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.11669\/cpj.2017.02.016","article-title":"The established of pediatric-focused adverse drug event triggers based on GTT by using Delphi method","volume":"52","author":"Huan-huana","year":"2017","journal-title":"Chin. Pharm. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/all.14090","article-title":"Gaps between actual initial treatment of anaphylaxis in China and international guidelines: A review and analysis of 819 reported cases","volume":"75","author":"Jiang","year":"2020","journal-title":"Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0091-6749(95)70329-2","article-title":"Underreporting of anaphylaxis in a community emergency room","volume":"95","author":"Klein","year":"1995","journal-title":"J. Allergy Clin. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/j.1365-2222.2011.03779.x","article-title":"Anaphylaxis: Mechanisms and management","volume":"41","author":"Lee","year":"2011","journal-title":"Clin. Exp. Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00228-018-2455-z","article-title":"Active pharmacovigilance in China: Recent development and future perspectives","volume":"74","author":"Li","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3760\/cma.j.issn.1008-5734.2019.02.002","article-title":"Recommendations in guideline for emergency management of anaphylaxis","volume":"21","author":"Li","year":"2019","journal-title":"Adverse Drug React. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11882-010-0154-7","article-title":"Perspectives on anaphylaxis epidemiology in the United States with new data and analyses","volume":"11","author":"Mulla","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI guidelines: Anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.waojou.2022.100689","article-title":"Incidence, triggering factors, symptoms, and treatment of anaphylaxis in a pediatric hospital","volume":"15","author":"Nunes","year":"2022","journal-title":"World Allergy Organ J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.iac.2017.06.003","article-title":"Platinum chemotherapy hypersensitivity: Prevalence and management","volume":"37","author":"Otani","year":"2017","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/all.12272","article-title":"The epidemiology of anaphylaxis in Europe: A systematic review","volume":"68","author":"Panesar","year":"2013","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.alit.2017.02.008","article-title":"Epidemiology of drug-induced anaphylaxis in a tertiary hospital in Korea","volume":"66","author":"Park","year":"2017","journal-title":"Allergol. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1188\/19.Cjon.68-75","article-title":"Oxaliplatin: Detection and management of hypersensitivity reactions","volume":"23","author":"Rogers","year":"2019","journal-title":"Clin. J. Oncol. Nurs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: Summary report-second national institute of allergy and infectious disease\/food allergy and anaphylaxis network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann. Emerg. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1258\/jrsm.2008.070306","article-title":"Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England","volume":"101","author":"Sheikh","year":"2008","journal-title":"J. R. Soc. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1067\/mai.2002.127860","article-title":"Epinephrine dispensing patterns for an out-of-hospital population: A novel approach to studying the epidemiology of anaphylaxis","volume":"110","author":"Simons","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.1866","article-title":"Incidence of adverse drug reactions in COVID-19 patients in China: An active monitoring study by hospital pharmacovigilance system","volume":"108","author":"Sun","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13223-018-0234-0","article-title":"Critical view of anaphylaxis epidemiology: Open questions and new perspectives","volume":"14","author":"Tanno","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/cea.12418","article-title":"Epidemiology of anaphylaxis","volume":"45","author":"Tejedor Alonso","year":"2015","journal-title":"Clin. Exp. Allergy"},{"key":"B29","first-page":"163","article-title":"Epidemiology of anaphylaxis: Contributions from the last 10 years","volume":"25","author":"Tejedor-Alonso Ma","year":"2015","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaip.2019.11.027","article-title":"Global trends in anaphylaxis epidemiology and clinical implications","volume":"8","author":"Turner","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaip.2022.09.019","article-title":"Anaphylaxis: Advances in the past 10 years","volume":"11","author":"Weiler","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (faers)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B33","volume-title":"Modern epidemiology methods and applications","author":"Zeng","year":"1996"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1180685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T04:35:05Z","timestamp":1689050105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1180685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":33,"alternative-id":["10.3389\/fphar.2023.1180685"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1180685","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"article-number":"1180685"}}